Copyright Bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world Novartis AG’s profit rose last quarter, buoyed by a suite of new cancer medicines. Core operating profit climbed 6% to $5.46 billion in the third quarter, the Swiss drugmaker said Tuesday, roughly matching analysts’ estimates. Sales were helped by the breast cancer medicine Kisqali, Pluvicto for prostate cancer and the leukemia drug Scemblix.
